Provided by Tiger Trade Technology Pte. Ltd.

Dolby Laboratories

64.36
+1.742.77%
Volume:624.44K
Turnover:39.90M
Market Cap:6.03B
PE:27.40
High:64.36
Open:62.36
Low:62.36
Close:62.62
52wk High:73.01
52wk Low:48.26
Shares:93.67M
Float Shares:58.75M
Volume Ratio:0.85
T/O Rate:1.06%
Dividend:1.44
Dividend Rate:2.24%
EPS(TTM):2.35
EPS(LYR):2.62
ROE:8.76%
ROA:5.15%
PB:2.33
PE(LYR):24.56

Loading ...

Dolby Laboratories Is Maintained at Outperform by Barrington Research

Dow Jones
·
Apr 27

Will Dolby’s Expanded Atmos and Vision Footprint in Cinemas and BMWs Change Dolby Laboratories' (DLB) Narrative

Simply Wall St.
·
Apr 27

Dolby showcases expanded in-car entertainment partnerships at Auto China 2026

Reuters
·
Apr 24

Earning Preview: Dolby Laboratories Q2 revenue is expected to increase by 2.50%, and institutional views are predominantly bullish

Earnings Agent
·
Apr 23

Dolby, BMW roll out Dolby Atmos in BMW 7 Series audio systems

Reuters
·
Apr 22

Dolby partners with EVO Entertainment to install Dolby Vision, Atmos in EVX auditoriums

Reuters
·
Apr 16

Dolby to report Q2 results, host conference call and webcast after market close

Reuters
·
Apr 09

Assessing Dolby Laboratories (DLB) Valuation After Recent Share Price Pullback

Simply Wall St.
·
Apr 08

Dolby director Emily Rollins disposes of DLB shares worth 0.1 million

Reuters
·
Apr 04

A Look At Dolby Laboratories (DLB) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 30

Is Dolby Laboratories (DLB) Offering Value After Recent Share Price Pullback

Simply Wall St.
·
Mar 28

Dolby Laboratories partners with QQ Music; Dolby Atmos rollout on QQ Music app grows via Dolby AC-4 enhancements

Reuters
·
Mar 27

Press Release: Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Dow Jones
·
Mar 26

Assessing Dolby Laboratories (DLB) Valuation After A Year Of Weaker Shareholder Returns

Simply Wall St.
·
Mar 20

CervoMed’s neflamapimod shows efficacy in dementia with DLB

TIPRANKS
·
Mar 19

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

GlobeNewswire
·
Mar 17

Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Dow Jones
·
Mar 17